308 related articles for article (PubMed ID: 29175369)
21. Incapacitating solar urticaria: successful treatment with omalizumab.
Kieselova K; Santiago F; Henrique M
An Bras Dermatol; 2019 Jul; 94(3):331-333. PubMed ID: 31365663
[TBL] [Abstract][Full Text] [Related]
22. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
[No Abstract] [Full Text] [Related]
23. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
Gericke J; Metz M; Ohanyan T; Weller K; Altrichter S; Skov PS; Falkencrone S; Brand J; Kromminga A; Hawro T; Church MK; Maurer M
J Allergy Clin Immunol; 2017 Mar; 139(3):1059-1061.e1. PubMed ID: 27838346
[No Abstract] [Full Text] [Related]
24. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
Cakmak ME
Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
[TBL] [Abstract][Full Text] [Related]
25. Real-life treatment of cholinergic urticaria with omalizumab.
Altrichter S; Chuamanochan M; Knoth H; Asady A; Ohanyan T; Metz M; Maurer M
J Allergy Clin Immunol; 2019 Feb; 143(2):788-791.e8. PubMed ID: 30312709
[No Abstract] [Full Text] [Related]
26. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
Ghazanfar MN; Bartko EA; Arildsen NS; Poulsen LK; Jensen BM; Enevold C; Holm JG; Woetmann A; Ødum N; Thomsen SF
Clin Exp Allergy; 2022 May; 52(5):715-718. PubMed ID: 35278253
[No Abstract] [Full Text] [Related]
27. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?
Asero R
Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398
[No Abstract] [Full Text] [Related]
28. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
29. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria.
Maurer M; Kolkhir P; Moñino-Romero S; Metz M
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668
[No Abstract] [Full Text] [Related]
30. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
[No Abstract] [Full Text] [Related]
31. Efficacy of omalizumab in severe chronic spontaneous urticaria: Real life data from a Greek tertiary center.
Kyriakou A; Trigoni A; Sotiriadis D; Patsatsi A
Dermatol Ther; 2018 Nov; 31(6):e12739. PubMed ID: 30194796
[No Abstract] [Full Text] [Related]
32. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
[No Abstract] [Full Text] [Related]
33. Use of omalizumab in the treatment of chronic urticaria.
Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
[TBL] [Abstract][Full Text] [Related]
34. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study.
Serarslan G; Uzun M; Doğramacı AÇ; Çelik E
Dermatol Ther; 2019 Jan; 32(1):e12752. PubMed ID: 30238582
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
[No Abstract] [Full Text] [Related]
36. Omalizumab as Third-Line Therapy for Urticaria During Pregnancy.
Ensina LF; Cusato-Ensina AP; Camelo-Nunes IC; Solé D
J Investig Allergol Clin Immunol; 2017; 27(5):326-327. PubMed ID: 29057743
[No Abstract] [Full Text] [Related]
37. Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study.
Asero R
Eur Ann Allergy Clin Immunol; 2022 Jan; 54(1):30-33. PubMed ID: 33555151
[No Abstract] [Full Text] [Related]
38. Effectiveness of omalizumab in severe solar urticaria.
de Dios-Velázquez Á; González-de Arriba M; Beteta-Gorriti V; Macías E; Campanón-Toro V; Dávila I
Ann Allergy Asthma Immunol; 2016 Mar; 116(3):260-2. PubMed ID: 26803538
[No Abstract] [Full Text] [Related]
39. Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients.
Vadasz Z; Tal Y; Rotem M; Shichter-Confino V; Mahlab-Guri K; Graif Y; Kessel A; Agmon-Levin N; Maoz-Segal R; Kivity S; Benor S; Lachover-Roth I; Zeldin Y; Stein M; Toker O; Hassoun G; Bezalel-Rosenberg S; Toubi E; Asher I; Sthoeger Z;
J Allergy Clin Immunol Pract; 2017; 5(6):1743-1745. PubMed ID: 28988786
[No Abstract] [Full Text] [Related]
40. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
